메뉴 건너뛰기
Blood Cancer Journal
Volumn 7, Issue 12, 2017, Pages
Clinically meaningful benefit: Real world use compared against the American and European guidelines
Author keywords

[No Author keywords available]
Indexed keywords

ACUTE MYELOID LEUKEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL OUTCOME; CLINICALLY MEANINGFUL BENEFIT; COLORECTAL CANCER; COMPARATIVE STUDY; EUROPE; GERM CELL TUMOR; GLIOBLASTOMA; HUMAN; LETTER; MALIGNANT NEOPLASM; MEDICAL LITERATURE; MELANOMA; MYELOPROLIFERATIVE NEOPLASM; NEOADJUVANT CHEMOTHERAPY; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; ONCOLOGY; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SYSTEMATIC REVIEW; THYROID CANCER; WESTERN HEMISPHERE; DISEASE FREE SURVIVAL; MORTALITY; NEOPLASM; TREATMENT OUTCOME; UNITED STATES;
EID: 85037978035     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/s41408-017-0009-8     Document Type: Letter
Times cited : (6)
References (6)
  • 1
    • 33845444046 scopus 로고    scopus 로고
    • Five-year follow-up of patients receiving imatinib for chronic myeloid Leukemia
    • Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid Leukemia. N. Engl. J. Med. 355, 2408-2417 (2006)
    • (2006) N. Engl. J. Med , vol.355 , pp. 2408-2417
    • Druker, B.J.1
  • 2
    • 84919725208 scopus 로고    scopus 로고
    • Unintended consequences of expensive cancer therapeutics\-The pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The john conley lecture
    • Fojo, T., Mailankody, S. &Lo, A. Unintended consequences of expensive cancer therapeutics\-The pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the john conley lecture. JAMA. Otolaryngol.-Head Neck Surg. 140, 1225-1236 (2014)
    • (2014) JAMA. Otolaryngol.-Head Neck Surg , vol.140 , pp. 1225-1236
    • Fojo, T.1    Mailankody, S.2    Lo, A.3
  • 3
    • 84899911233 scopus 로고    scopus 로고
    • American society of clinical oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes
    • Ellis, L. M. et al. American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol. 32, 1277-1280 (2014)
    • (2014) J. Clin. Oncol , vol.32 , pp. 1277-1280
    • Ellis, L.M.1
  • 4
    • 84940648261 scopus 로고    scopus 로고
    • A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The european society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS)
    • Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26, 1547-1573 (2015)
    • (2015) Ann. Oncol , vol.26 , pp. 1547-1573
    • Cherny, N.I.1
  • 5
    • 85010310954 scopus 로고    scopus 로고
    • Appraisal of clinically meaningful outcomes guidelines for oncology clinical trials
    • Kumar, H., Fojo, T. &Mailankody, S. A. N. Appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol. 2, 1238-1240 (2016)
    • (2016) JAMA Oncol , vol.2 , pp. 1238-1240
    • Kumar, H.1    Fojo, T.2    Mailankody, S.A.N.3
  • 6
    • 85015742215 scopus 로고    scopus 로고
    • Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? Ann
    • Paggio J. C. et al. Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? Ann. Oncol. 28, 157-162 (2017)
    • (2017) Oncol , vol.28 , pp. 157-162
    • Paggio, J.C.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.